Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Piroxicam ( BAYl1902)
Piroxicam · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | EXPERIMENTAL | - |
| Arm 3 | PLACEBO_COMPARATOR | - |
| Arm 4 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Piroxicam ( BAYl1902) | DRUG | Single dose of 20 mg piroxicam (i.e., 1 piroxicam capsule + 3 placebo capsule) |
| Placebo | DRUG | Single dose of placebo (i.e., 4 placebo capsules) |
Inclusion Criteria: * Signed informed consent available before any study specific tests or procedures are performed * Healthy female subject * Age: 18 to 35 years (inclusive) at the first screening visit * Body mass index (BMI ): 18-30 kg/m² (inclusive) at the first screening visit * Confirmation o...
Piroxicam is being studied as a postcoital contraceptive, meaning it is taken after intercourse to prevent pregnancy. It is a small molecule developed by Bayer AG under the ticker BAYRY. The research is at Phase 2, so it is investigational and not an approved contraceptive method.
Piroxicam targets PTGS2 and PTGS1, also known as cyclooxygenase-2 and cyclooxygenase-1. It acts as an inhibitor of these enzymes. This target class is the basis for its investigation in postcoital contraception, where prostaglandin synthesis is thought to play a role in ovulation and fertilization.
Piroxicam is developed by Bayer AG, which trades under the ticker BAYRY. Bayer is the sponsor behind the clinical research into the drug for postcoital contraception. The compound is a small molecule and is also referenced in the literature as BAYl1902.
Piroxicam is in Phase 2 development for postcoital contraception. It is investigational and has not been approved for this use. The Phase 2 program includes one completed trial, and there are currently no active trials listed for this indication.
Piroxicam has been studied in one completed Phase 2 trial, NCT01320709, titled Effect of Piroxicam on Ovulation. That trial enrolled 72 female healthy volunteers aged 18 years and older in Germany. It was randomized, double-blind, and placebo-controlled. No active trials are currently listed.
Yes, BAYl1902 is an alternative designation for Piroxicam. Both names refer to the same small molecule developed by Bayer AG. The compound is identified in chemical databases under the ChEMBL ID CHEMBL527.